VCP downstream metabolite glycerol-3-phosphate (G3P) inhibits CD8+T cells function in the HCC microenvironment by Cheng Cheng, Qingrui Zha, Linmao Sun, Tianming Cui, Xinyu Guo, Changjian Xing, Zhengxiang Chen, Changyong Ji, Shuhang Liang, Shengwei Tao, Junhui Chu, Chenghui Wu, Qi Chu, Xuetian Gu, Ning Zhang, Yumin Fu, Shumin Deng, Yitong Zhu, Jiabei Wang, Yao Liu, Lianxin Liu

“…The accumulated G3P diffuses into the TME and directly interacts with SRC-family tyrosine kinase LCK, a critical component of the T-cell receptor (TCR) signaling pathway in CD8+T cells. …”
Get full text

Exploring precision therapeutics: computational design of antisense oligonucleotides targeting AXL gene transcripts in multiple sclerosis treatment management by Bhargav Shreevatsa, Bhargav Shreevatsa, Abhigna Nagaraj, Chandan Dharmashekar, Anisha Jain, Bhavana Harendra, Siddesh V. Siddalingegowda, Haneen A. Al-Mazroua, Sheikh F. Ahmad, Shashanka K. Prasad, Chandrashekar Srinivasa, Chandan Shivamallu, Shiva Prasad Kollur

“…The AXL gene, which codes for a receptor tyrosine kinase, has emerged as a promising therapeutic target due to its involvement in neuroinflammation and oligodendrocyte dysfunction. …”
Get full text

Gene Expression Pattern and Regulatory Network of α-Toxin Treatment in Bombyx mori by Tieshan Feng, Ping Lin, Jiao Gong, Dong Cheng, Xi Yang, Quan Zhang, Tingcai Cheng

“…The upregulated genes in the midgut were mainly involved in peptidoglycan catabolic process and tyrosine kinase signaling pathway, whereas the downregulated genes were mainly involved in chitin metabolic pathways. …”
Get full text

Role of the Btk-PLCγ2 Signaling Pathway in the Bone Destruction of Apical Periodontitis by Lina Wang, Hong Zhang, Ming Dong, Meina Zuo, Shuo Liu, Ying Lu, Weidong Niu

“…Studies have shown that the Bruton tyrosine kinase- (Btk-) phospholipase Cγ2 (PLCγ2) signaling pathway plays an important role in bone absorption, but it is unknown whether it plays a role in apical periodontitis bone destruction. …”
Get full text

Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia by Qi Zhou, Yongyu Guan, Pingping Zhao, Huiyuan Chu, Yaming Xi

“…Gilteritinib treats acute myeloid leukemia (AML) with the FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation. …”
Get full text

Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY by Jill Feldman, MA, Ivy Elkins, MBA, Zofia Piotrowska, MD, Bellinda L. King-Kallimanis, PhD, Tendai Chihuri, MD, Carly Johnson, BS, Alecia Clary, PhD, Teri Kennedy, MA, Upal Basu Roy, PhD, MPH

“…In addition, 89% reported receiving at least one tyrosine kinase inhibitor (TKI); osimertinib was the most prescribed first-line TKI for stage IV participants diagnosed after 2017. …”
Get full text

Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study by Geke Zhu, Han Zhou, Wanying Wang, Yongbo Ma, Xiangtao Nie, Wenjing Qi, Lei Hao, Xiuming Guo

“…During the 8-week follow-up, in GMG patients, whether positive for acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) antibodies, the overall efficacy was significant. …”
Get full text

Pharmacovigilance imbalance analysis of VEGFR-TKI-related taste and smell disorders by Zhong-hua Fu, Chenglong Zhao, Yaqin Wang, Lei Zhang, Lei Wang

“…The advent of targeted drugs such as vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) has significantly extended the survival time of cancer patients, and thus widely used in clinical practice. …”
Get full text

Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages by Yuan Li, Yanping Chen, Yuan Meng, Meng Shen, Fan Yang, Xiubao Ren

“…Objective: The combination of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) leads to an increased incidence of severe immune-related adverse events (irAEs). …”
Get full text

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort by Hilin Yildirim, Anke Richters, Adriaan D. Bins, Arnoud W. Postema, Maureen J.B. Aarts, Martijn G.H. van Oijen, Patricia J. Zondervan, Katja K.H. Aben

“…Targeted therapy with tyrosine kinase inhibitors (TKIs) was the standard of care for metastatic renal cell carcinoma (mRCC) until recently, when new first-line combinations with immuno-oncology (IO) agents were approved. …”
Get full text

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation by Chang Dong Yeo, Dong Won Park, Seong Hoon Yoon, Eun Young Kim, Jeong Eun Lee, Shin Yup Lee, Chang‐Min Choi, In‐Jae Oh, Do Jin Kim, Jeong Seon Ryu, Jae Cheol Lee, Young‐Chul Kim, Tae Won Jang, Kye Young Lee, Seung Hun Jang, Seung Joon Kim, for the Korean EGFR Registry Investigators

“…Moreover, it will investigate various aspects, including the safety and efficacy of a new third‐generation EGFR tyrosine kinase inhibitor (TKI), lazertinib, approved for both first‐ and second‐line treatments. …”
Get full text

Cross-Talk between NOK and EGFR: Juxtamembrane and Kinase domain interactions enhancing STAT3/5 signaling in breast cancer tumorigenesis by Yinyin Wang, Bingdong Zhang, Chunhua He, Bo Tian, Sihan Liu, Jianghua Li, Jiayu Wang, Shigao Yang, Bingtao Zhu, Xiaoguang Wang, Zhijie Chang, Chenxi Cao

“…Here we report that NOK (also known as STYK1), a novel tyrosine kinase cross-talks with EGFR to promote tumorigenesis and metastasis of breast cancer cells. …”
Get full text

Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients by Umberto Basile, Mariapaola Marino, Cecilia Napodano, Krizia Pocino, Paolo Emilio Alboini, Francesca Gulli, Amelia Evoli, Carlo Provenzano, Emanuela Bartoccioni

“…Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction with antibodies (abs) targeting the acetylcholine receptor (AChR) or the muscle-specific tyrosine kinase (MuSK), inducing muscle weakness and excessive fatigability. …”
Get full text

Nicotine is associated with smoking dependence and vascular inflammation through cotinine: A mediation analysis by Kumboyono Kumboyono, Indah N. Chomsy, Nadya N. Shalshabilla, Hidayat Sujuti, Arie Srihardyastutie, Cholid T. Tjahjono, Teuku Heriansyah, Titin A. Wihastuti

“…This study aimed to evaluate the relationship between NO levels and cotinine through the expression of nAChRs that mediate the nicotine dependence mechanism and Tie2 (Tyrosine Kinase 2) expression. Methods A cross-sectional study was conducted with 200 participants grouped into two groups based on their smoking status: 100 smokers and 100 non-smokers. …”
Get full text

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy by Meng-Tung Hsu, Gerald Willimsky, Gerald Willimsky, Gerald Willimsky, Leo Hansmann, Leo Hansmann, Leo Hansmann, Leo Hansmann, Thomas Blankenstein

“…BCR-ABL kinase is the major oncogenic driver of chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs), which are highly potent in targeting BCR-ABL, are currently used as first-line treatment. …”
Get full text

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report by Oliver Illini, Anna Sophie Lang-Stöberl, Hannah Fabikan, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair

“…New agents, including zongertinib, a HER2-selective tyrosine kinase inhibitor (TKI), are being investigated in clinical trials. …”
Get full text

Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective by Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin

“…**Background:** Tyrosine kinase inhibitors (TKIs) are the standard-of-care treatment for chronic myeloid leukemia in chronic phase (CML-CP). …”
Get full text

Novel genes involved in vascular dysfunction of the middle temporal gyrus in Alzheimer’s disease: transcriptomics combined with machine learning analysis by Meiling Wang, Aojie He, Yubing Kang, Zhaojun Wang, Yahui He, Kahleong Lim, Chengwu Zhang, Li Lu

“…Two subtypes of middle temporal gyrus cells showed significant alteration in AD: endothelial cells with high expression of Erb-B2 receptor tyrosine kinase 4 (ERBB4high) and pericytes with high expression of angiopoietin-like 4 (ANGPTL4high). …”
Get full text

Magnetic Resonance Imaging Combined with Serological Markers Improves the Diagnosis of Placenta Previa with Placenta Accreta Spectrum by Ying Wang, Zhengdong Hou, Bingqing Xia, Xianjing Xie, Ying He

“…The aim of this study was to evaluate the accuracy of magnetic resonance imaging (MRI) combined with three serological markers (alpha-fetoprotein [AFP], creatine kinase [CK], and soluble fms-like tyrosine kinase-1 [sFlt-1]) for the diagnosis of PP with PAS. …”
Get full text

Inhibition of TFF3 synergizes with c-MET inhibitors to decrease the CSC-like phenotype and metastatic burden in ER+HER2+ mammary carcinoma by Chuyu He, Xuejuan Wang, Yi-Shiou Chiou, Basappa Basappa, Tao Zhu, Vijay Pandey, Peter E. Lobie

“…Furthermore, a high-throughput combinatorial anti-cancer compound library screening revealed that AMPC preferentially synergized with receptor tyrosine kinase c-MET inhibitors (c-METis) to reduce cell survival and the CSC-like phenotype. …”
Get full text